Bioxytran, Inc BIXT
We take great care to ensure that the data presented and summarized in this overview for BIOXYTRAN, INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in BIXT
Top Purchases
Top Sells
About BIXT
Bioxytran, Inc., a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing. It is also developing ProLectin-Rx, a polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin for treatment of mild to moderate cases of Covid-19. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Insider Transactions at BIXT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 19
2024
|
Ola Soderquist CFO |
BUY
Other acquisition or disposition
|
Direct |
3,907,060
+50.0%
|
$0
$0.05 P/Share
|
|
Aug 19
2024
|
Ola Soderquist CFO |
SELL
Other acquisition or disposition
|
Direct |
19,535,300
-100.0%
|
-
|
|
Aug 19
2024
|
Michael Sheikh Chief Communications Officer |
BUY
Other acquisition or disposition
|
Direct |
1,600,000
+50.0%
|
$0
$0.02 P/Share
|
|
Aug 19
2024
|
Michael Sheikh Chief Communications Officer |
SELL
Other acquisition or disposition
|
Direct |
8,000,000
-100.0%
|
-
|
|
Aug 19
2024
|
Radka Milanova Director |
BUY
Other acquisition or disposition
|
Direct |
36,529
+50.0%
|
$0
$0.66 P/Share
|
|
Aug 19
2024
|
Radka Milanova Director |
SELL
Other acquisition or disposition
|
Direct |
182,645
-100.0%
|
$0
$0.13 P/Share
|
|
Aug 19
2024
|
David Platt CEO |
BUY
Other acquisition or disposition
|
Direct |
8,605,455
+50.0%
|
-
|
|
Aug 19
2024
|
David Platt CEO |
SELL
Other acquisition or disposition
|
Direct |
43,027,274
-100.0%
|
-
|
|
Aug 19
2024
|
David Platt CEO |
BUY
Other acquisition or disposition
|
Indirect |
5,194,265
+35.08%
|
$0
$0.42 P/Share
|
|
Aug 19
2024
|
David Platt CEO |
SELL
Other acquisition or disposition
|
Indirect |
22,087,239
-100.0%
|
$0
$0.08 P/Share
|
|
Aug 19
2024
|
David Platt CEO |
BUY
Conversion of derivative security
|
Indirect |
8,973,405
+40.27%
|
$0
$0.02 P/Share
|
|
Aug 19
2024
|
Anders Utter Director |
BUY
Other acquisition or disposition
|
Direct |
215,838
+50.0%
|
$0
$0.82 P/Share
|
|
Aug 19
2024
|
Anders Utter Director |
SELL
Other acquisition or disposition
|
Direct |
1,079,189
-100.0%
|
$0
$0.16 P/Share
|
|
Aug 19
2024
|
Dale H Conaway Director |
BUY
Other acquisition or disposition
|
Direct |
212,018
+50.0%
|
$0
$0.84 P/Share
|
|
Aug 19
2024
|
Dale H Conaway Director |
BUY
Other acquisition or disposition
|
Direct |
1,060,089
+100.0%
|
$0
$0.17 P/Share
|
|
Aug 19
2024
|
Alan M Hoberman Director |
BUY
Other acquisition or disposition
|
Direct |
226,678
+50.0%
|
$0
$0.8 P/Share
|
|
Aug 19
2024
|
Alan M Hoberman Director |
SELL
Other acquisition or disposition
|
Direct |
1,133,389
-100.0%
|
$0
$0.16 P/Share
|
|
Aug 16
2024
|
Radka Milanova Director |
BUY
Grant, award, or other acquisition
|
Direct |
82,645
+31.15%
|
$0
$0.12 P/Share
|
|
Aug 16
2024
|
Anders Utter Director |
BUY
Grant, award, or other acquisition
|
Direct |
123,967
+10.3%
|
$0
$0.12 P/Share
|
|
Aug 16
2024
|
Dale H Conaway Director |
BUY
Grant, award, or other acquisition
|
Direct |
123,967
+10.47%
|
$0
$0.12 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 5.74M shares |
|---|---|
| Other acquisition or disposition | 21.1M shares |
| Conversion of derivative security | 8.97M shares |
| Open market or private purchase | 1.59M shares |
| Other acquisition or disposition | 95M shares |
|---|